Prashant Mujumdar

Prashant Mujumdar

Auto-generated profile, based on publicly available information

Prashant Mujumdar

Griffith Institute for Drug Discovery, Griffith University, Brisbane, Nathan, Queensland, Australia

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2015 in Journal of Natural Products
Verified
Journal Article
Closed access
PMPrashant Mujumdar
Prashant Mujumdar
SPSally-Ann Poulsen
Sally-Ann Poulsen

12 May 2016 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PMPrashant Mujumdar
Prashant Mujumdar
KTKanae Teruya
Kanae Teruya
KTKathryn F Tonissen
Kathryn F Tonissen
DVDaniela Vullo
Daniela Vullo
Claudiu SupuranClaudiu Supuran
Claudiu Supuran
SPSally-Ann Poulsen
Sally-Ann Poulsen

1 December 2018 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
Iris Chiara SalaroglioIris Chiara Salaroglio
Iris Chiara Salaroglio
PMPrashant Mujumdar
Prashant Mujumdar
LALaura Annovazzi
Laura Annovazzi
JKJoanna Kopecka
Joanna Kopecka
MMMarta Mellai
Marta Mellai
Chiara RigantiChiara Riganti
Chiara Riganti
The role of carbonic anhydrase XII (CAXII) in the chemoresistance of glioblastoma is unexplored. We found CAXII and P-glycoprotein (Pgp) coexpressed in neurospheres derived from 3 of 3 patients with different genetic backgrounds and low response to temozolomide (time to recurrence: 6–9 months). CAXII was necessary for the Pgp efflux of temozolomide and second-line chemotherapeutic drugs, determining chemoresistance in neurospheres. Psammaplin C, a potent inhibitor of CAXII, resensitized primary neurospheres to temozolomide by reducing temozolomide efflux via Pgp. This effect was independent of other known temozolomide resistance factors present in the patients. The overall survival in orthotopic patient-derived xenografts of temozolomide-resistant neurospheres, codosed with Psammaplin C and temozolomide, was significantly increased over temozolomide-treated (P < 0.05) and untreated animals (P < 0.02), without detectable signs of systemic toxicity. We propose that a CAXII inhibitor in combination with temozolomide may provide a new and effective approach to reverse chemoresistance in glioblastoma stem cells. This novel mechanism of action, via the interaction of CAXII and Pgp, ultimately blocks the efflux function of Pgp to improve glioblastoma patient outcomes.

1 September 2014 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PSPakornwit Sarnpitak
Pakornwit Sarnpitak
PMPrashant Mujumdar
Prashant Mujumdar
CMChristophe Morisseau
Christophe Morisseau
SHSung Hee Hwang
Sung Hee Hwang
BHBruce Hammock
Bruce Hammock
Mikhail KrasavinMikhail Krasavin
Mikhail Krasavin

1 September 2017 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PCPanagiotis K. Chrysanthopoulos
Panagiotis K. Chrysanthopoulos
PMPrashant Mujumdar
Prashant Mujumdar
LWLucy A. Woods
Lucy A. Woods
ODOlan Dolezal
Olan Dolezal
BRBin Ren
Bin Ren
SPSally-Ann Poulsen
Sally-Ann Poulsen

1 June 2011 in Tetrahedron: Asymmetry
Verified
Journal Article
Closed access
MMM. Muthukrishnan
M. Muthukrishnan
MMM. Mujahid
M. Mujahid
MSM. Sasikumar
M. Sasikumar
PMP. Mujumdar
P. Mujumdar